Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopropyl Alcohol SCHEMBL29153000 | 0.87 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPK1TSHRTDP1 | |
| SCHEMBL9694648 | 0.86 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPK1 | |
| Hexane SCHEMBL15970043 | 0.83 | ALDH1A1 (0.42) | ALDH1A1LMNAMAPK1TSHR | |
| Propylene Glycol SCHEMBL8572846 | 0.81 | TDP1 (0.59) | ALDH1A1LMNAMAPK1TSHRTDP1 | |
| Heptane SCHEMBL14119566 | 0.81 | SPHK1 (0.41) | ALDH1A1LMNATSHR | |
| Hexane SCHEMBL28859861 | 0.81 | ALDH1A1 (0.40) | ALDH1A1LMNAMAPK1TSHR | |
| Methyl Alcohol SCHEMBL1151710 | 0.79 | — | — | |
| SCHEMBL8679785 | 0.78 | ALDH1A1 (1.00) | ALDH1A1TSHRTDP1 | |
| SCHEMBL6223 | 0.78 | — | — | |
| SCHEMBL503396 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118191080-A | Method for detecting isoniazid and ethionamide in blood | 中国科学院大连化学物理研究所 | 2024-06-14 | — | — | CN | claimed |
| WO-2023051753-A1 | PREPARATION METHOD FOR ROCK INHIBITOR, INTERMEDIATE THEREOF AND PREPARATION METHOD FOR INTERMEDIATE | 武汉朗来科技发展有限公司 | 2023-04-06 | — | — | WO | claimed |
| CN-115894463-A | Preparation method of ROCK inhibitor, intermediate thereof and preparation method of intermediate | 武汉朗来科技发展有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-112745268-B | Crystal form of benzimidazole derivative and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-09-16 | — | — | CN | claimed |
| CN-114230503-A | Method for synthesizing vildagliptin by one-pot method | 山东安舜制药有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-112745268-A | Crystal form of benzimidazole derivative and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2021-05-04 | — | — | CN | claimed |
| CN-110483520-B | Crystal form of Bruton's tyrosine kinase inhibitor, preparation method and application thereof | 杭州和正医药有限公司 | 2021-04-16 | — | — | CN | claimed |
| US-10899744-B2 | Crystalline form of compound suppressing protein kinase activity, and application thereof | XCOVERY HOLDINGS, INC. (US) | 2021-01-26 | — | — | US | claimed |
| CN-112079739-A | Preparation method of azelastine key intermediate N-methylhexahydroazepin-4-one hydrochloride | 四川伊诺达博医药科技有限公司 | 2020-12-15 | — | — | CN | claimed |
| CN-105399771-B | Tenofovir prodrug crystal form and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2020-11-24 | — | — | CN | claimed |
| WO-2012156382-A1 | NOVEL CRYSTALLINE ASENAPINE HYDROCHLORIDE SALT FORMS | SANDOZ AG (CH) | 2012-11-22 | — | — | WO | claimed |
| EP-2524920-A1 | Novel Crystalline Asenapine Hydrochloride Salt Forms | Sandoz AG (CH) | 2012-11-21 | — | — | EP | claimed |
| US-8183370-B2 | Process for the preparation of abacavir | ESTEVE QUIMICA, SA (ES) | 2012-05-22 | — | — | US | claimed |
| CN-101522680-B | Process for the preparation of abacavir | ESTEVE QUIMICA SA | 2012-04-18 | — | — | CN | claimed |
| US-20100004446-A1 | Process for the Preparation of Abacavir | Esteve Química, S.A. (ES) | 2010-01-07 | — | — | US | claimed |
| CN-101522680-A | Process for the preparation of abacavir | ESTEVE QUIMICA SA (ES) | 2009-09-02 | — | — | CN | claimed |
| EP-2079741-A1 | PROCESS FOR THE PREPARATION OF ABACAVIR | ESTEVE QUIMICA, S.A. (ES) | 2009-07-22 | — | — | EP | claimed |
| WO-2008037760-A1 | PROCESS FOR THE PREPARATION OF ABACAVIR | ESTEVE QUIMICA, S.A. (ES) | 2008-04-03 | — | — | WO | claimed |
| EP-1905772-A1 | Process for the preparation of abacavir | ESTEVE QUIMICA, S.A. (ES) | 2008-04-02 | — | — | EP | claimed |
| US-20060199958-A1 | Process and intermediates for the preparation of pyrrolidine carboxylic acids | MERCK & CO., INC. | 2006-09-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004446-A1 | Process for the Preparation of Abacavir | ALKBH1, ADAR, ADA | ALDH1A1 231/4885LMNA 2154/4885MAPK1 2191/4885 |
| US-20060199958-A1 | Process and intermediates for the preparation of pyrrolidine carboxylic acids | MC4R, MC5R, NPY4R | ALDH1A1 1480/4885LMNA 4776/4885MAPK1 1866/4885 |
| US-10899744-B2 | Crystalline form of compound suppressing protein kinase activity, and application thereof | MAPKAPK5, MAP3K6, MAP3K5 | ALDH1A1 4112/4885LMNA 2214/4885MAPK1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.